A clinical trial led by Stanford Medicine researchers has found that a 15-day course of Paxlovid, an antiviral drug targeting the virus that causes COVID-19, is safe as an extended treatment but does not alleviate select symptoms of long COVID. The findi… Read on blog or Reader ScienceBlog.com Read on blog or Reader 15-day Paxlovid regimen safe but adds no clear long-COVID benefit Stanford University June 9 A clinical trial led by Stanford Medicine researchers has found that a 15-day course of Paxlovid, an antiviral drug targeting the virus that causes COVID-19, is safe as an extended treatment but does not alleviate select symptoms of long COVID. The findings, described in a paper published June 7 in JAMA Internal Medicine, offer a […] Continue reading

ScienceBlog.com © 2024. Manage your email settings or unsubscribe. Get the Jetpack app Subscribe, bookmark, and get real-time notifications - all from one app! Automattic, Inc. - 60 29th St. #343, San Francisco, CA 94110